BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24419084)

  • 1. LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors.
    de la Roche M; Ibrahim AE; Mieszczanek J; Bienz M
    Cancer Res; 2014 Mar; 74(5):1495-505. PubMed ID: 24419084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.
    de la Roche M; Worm J; Bienz M
    BMC Cancer; 2008 Jul; 8():199. PubMed ID: 18627596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.
    Adachi S; Jigami T; Yasui T; Nakano T; Ohwada S; Omori Y; Sugano S; Ohkawara B; Shibuya H; Nakamura T; Akiyama T
    Cancer Res; 2004 Dec; 64(23):8496-501. PubMed ID: 15574752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin.
    Lo YH; Noah TK; Chen MS; Zou W; Borras E; Vilar E; Shroyer NF
    Gastroenterology; 2017 Jul; 153(1):205-218.e8. PubMed ID: 28390865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
    Bao R; Christova T; Song S; Angers S; Yan X; Attisano L
    PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.
    Pedersen NM; Thorvaldsen TE; Schultz SW; Wenzel EM; Stenmark H
    PLoS One; 2016; 11(8):e0160507. PubMed ID: 27482906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tankyrase inhibition aggravates kidney injury in the absence of CD2AP.
    Kuusela S; Wang H; Wasik AA; Suleiman H; Lehtonen S
    Cell Death Dis; 2016 Jul; 7(7):e2302. PubMed ID: 27441654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
    Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
    PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of zinc-finger BED domain-containing 3 (Zbed3) as a novel Axin-interacting protein that activates Wnt/beta-catenin signaling.
    Chen T; Li M; Ding Y; Zhang LS; Xi Y; Pan WJ; Tao DL; Wang JY; Li L
    J Biol Chem; 2009 Mar; 284(11):6683-9. PubMed ID: 19141611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.
    Huang SM; Mishina YM; Liu S; Cheung A; Stegmeier F; Michaud GA; Charlat O; Wiellette E; Zhang Y; Wiessner S; Hild M; Shi X; Wilson CJ; Mickanin C; Myer V; Fazal A; Tomlinson R; Serluca F; Shao W; Cheng H; Shultz M; Rau C; Schirle M; Schlegl J; Ghidelli S; Fawell S; Lu C; Curtis D; Kirschner MW; Lengauer C; Finan PM; Tallarico JA; Bouwmeester T; Porter JA; Bauer A; Cong F
    Nature; 2009 Oct; 461(7264):614-20. PubMed ID: 19759537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
    de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
    Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
    Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
    J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
    Luo F; Li J; Liu J; Liu K
    Cancer Gene Ther; 2022 Nov; 29(11):1707-1719. PubMed ID: 35750753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
    Jang MK; Mashima T; Seimiya H
    Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.